Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
648 stopped studies mapped to Myeloid Leukemia and descendants · 88% state a reason
Over the 648 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06128044 | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With…(AMpLify) | Phase 1 | terminated | Nov 13, 2023 | Caribou Biosciences, Inc. | Sponsor Decision - Pipeline Reprioritization | Sponsor / business decision |
| NCT01751425 | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual… | Phase 1 | terminated | Dec 18, 2012 | M.D. Anderson Cancer Center | Per PI Request. 2) No additional benefit was noted with the addition of Ruxolitinib. | Other (stated, no rule matched) |
| NCT04789655 | Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2021 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not… | Phase 1 / Phase 2 | terminated | Jun 10, 2024 | Institute of Hematology & Blood Diseases Hospital, China | The number of participants in the study did not meet expectations | Other (stated, no rule matched) |
| NCT06572631 | Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for… | Phase 1 | withdrawn | Aug 27, 2024 | City of Hope Medical Center | cprmc withdrawn | Other (stated, no rule matched) |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of… | Phase 1 / Phase 2 | terminated | Feb 12, 2021 | M.D. Anderson Cancer Center | supporting/funding source decided to de-prioritize and stop development of DS-1594 | Funding |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute… | Phase 1 / Phase 2 | terminated | May 25, 2018 | Sumithira Vasu | Poor acccrual | Other (stated, no rule matched) |
| NCT05447663 | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute… | Phase 1 / Phase 2 | terminated | Jul 7, 2022 | Novartis Pharmaceuticals | Study has been stopped following the strategic decision from the Sponsor. Not based on any safety… | Safety / toxicity |
| NCT03286114 | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Phase 1 | terminated | Sep 18, 2017 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or… | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | M.D. Anderson Cancer Center | The study was terminated early due to slow accrual and low level of interest both by the sponsor… | Enrollment / accrual |
| NCT05038644 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic… | Phase 1 | terminated | Sep 9, 2021 | Ehab L Atallah | Drug expired May 31, 2024. | Other (stated, no rule matched) |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched… | Phase 2 | terminated | Feb 14, 2012 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT03560908 | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT… | Phase 1 | withdrawn | Jun 18, 2018 | Institute of Hematology & Blood Diseases Hospital, China | No enough eligable participants enrolled | Enrollment / accrual |
| NCT05595135 | Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute… | N/A | withdrawn | Oct 26, 2022 | Thomas Jefferson University | staffing | Other (stated, no rule matched) |
| NCT05766514 | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs.… | Phase 2 | withdrawn | Mar 13, 2023 | University of Florida | Study disapproved by internal scientific review committee on re-review; study will no longer move… | Other (stated, no rule matched) |
| NCT04185428 | Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia | N/A | terminated | Dec 4, 2019 | University of Florida | The PIs left the institution. | Other (stated, no rule matched) |
| NCT03038230 | MCLA-117 in Acute Myelogenous Leukemia | Phase 1 | terminated | Jan 31, 2017 | Merus B.V. | strategic considerations | Sponsor / business decision |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA… | Phase 2 | terminated | Aug 3, 2018 | Memorial Sloan Kettering Cancer Center | Low accrual | Enrollment / accrual |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in…(ENHANCE-3) | Phase 3 | terminated | Oct 15, 2021 | Gilead Sciences | Study was terminated due to futility | Efficacy / futility |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT06351306 | DEC-C and Thioguanine for R/R AML | Phase 2 | withdrawn | Apr 8, 2024 | Columbia University | Difficultly enrolling | Enrollment / accrual |
| NCT03746054 | Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the…(PALERMO) | Phase 3 | terminated | Nov 19, 2018 | University Hospital, Angers | Inclusions stopped on 25MAR2022 due to lack of inclusion Last follow-up on 16APR2024 | Other (stated, no rule matched) |
| NCT06113289 | A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | Phase 1 / Phase 2 | withdrawn | Nov 2, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04477291 | A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | Phase 1 | terminated | Jul 20, 2020 | Aptose Biosciences Inc. | Change in corporate strategy | Sponsor / business decision |
| NCT06068868 | Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in… | Phase 1 | terminated | Oct 5, 2023 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT06110208 | Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r… | Early Phase 1 | terminated | Oct 31, 2023 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Collaborator's decision | Other (stated, no rule matched) |
| NCT03686345 | Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor…(AML FLT3) | Phase 2 | terminated | Sep 26, 2018 | Niguarda Hospital | didn't reach the primary endpoint | Other (stated, no rule matched) |
| NCT04905407 | Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute… | Phase 2 | terminated | May 27, 2021 | Syros Pharmaceuticals | As per sponsor decision, the study was terminated. | Sponsor / business decision |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of…(ENHANCE-2) | Phase 3 | terminated | Mar 3, 2021 | Gilead Sciences | Study discontinued due to futility. | Efficacy / futility |
| NCT04342962 | Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia | Phase 2 | terminated | Apr 13, 2020 | Gruppo Italiano Malattie EMatologiche dell'Adulto | poor enrollment | Enrollment / accrual |
| NCT06200441 | Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and… | — | withdrawn | Jan 11, 2024 | Ugur Arzu Kulu | Kits were not available due to lack of sponsorship | Other (stated, no rule matched) |
| NCT01743807 | Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia | Phase 1 | terminated | Dec 6, 2012 | Therapeutic Advances in Childhood Leukemia Consortium | SBI Biotech (supplier) decided to no longer support the study or GNKG168. | Other (stated, no rule matched) |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | Phase 1 | terminated | May 14, 2021 | Lava Therapeutics | The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive… | Safety / toxicity |
| NCT02398825 | Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid… | Phase 2 | terminated | Mar 26, 2015 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low enrollment rate | Enrollment / accrual |
| NCT04914676 | Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With… | Phase 2 | terminated | Jun 4, 2021 | University of Florida | PI decision to close study early due to limited data due to accrual goal not being met | Enrollment / accrual |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic… | Phase 2 | terminated | Sep 10, 2019 | Fred Hutchinson Cancer Center | The federal funding period ended. The study was originally intended to be multi-site but was only… | Enrollment / accrual |
| NCT04029688 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of… | Phase 1 / Phase 2 | terminated | Jul 23, 2019 | Hoffmann-La Roche | Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed… | Efficacy / futility |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML(CYNK001AML01) | Phase 1 | terminated | Mar 17, 2020 | Celularity Incorporated | Business reasons | Sponsor / business decision |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory… | Phase 1 | terminated | Aug 26, 2020 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | Phase 1 | terminated | Feb 25, 2020 | Taiho Oncology, Inc. | The study was terminated due to the changing treatment landscape, difficulty in enrolling eligible… | Enrollment / accrual |
| NCT04582864 | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)… | Phase 2 | terminated | Oct 12, 2020 | Washington University School of Medicine | The sponsor is no longer supporting the drug | Other (stated, no rule matched) |
| NCT04755244 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia… | Phase 1 | terminated | Feb 16, 2021 | ALX Oncology Inc. | While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2. | Other (stated, no rule matched) |
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | Phase 1 | withdrawn | Mar 22, 2021 | Duke University | Study halted prematurely, prior to enrollment of first participant. | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05266950 | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory… | Phase 1 | withdrawn | Mar 4, 2022 | Beijing Boren Hospital | Difficulty in joining the group | Other (stated, no rule matched) |
| NCT04762875 | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in… | Phase 2 | terminated | Feb 21, 2021 | Ensoma | This study was voluntarily terminated due to a business decision not to proceed and not due to any… | Safety / toxicity |
| NCT05601466 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | Phase 1 | terminated | Nov 1, 2022 | Institute of Hematology & Blood Diseases Hospital, China | It did not reach the expected results of clinical trial | Other (stated, no rule matched) |
| NCT02610062 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of… | Phase 1 | terminated | Nov 20, 2015 | Astellas Pharma Global Development, Inc. | Business decision by sponsor | Sponsor / business decision |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade… | Phase 1 | withdrawn | Aug 21, 2020 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT02864290 | A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in… | Phase 1 | terminated | Aug 12, 2016 | Astellas Pharma Global Development, Inc. | Study was terminated due to lack of efficacy. | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 11, 2025source: clinicaltrials